PharmaCielo Reports Strong Q4 2024 Financial Results, Positioning Itself for Global Medicinal Cannabis Market

PharmaCielo Ltd. (TSXV: PCLO) (OTC: PCLOF), a global cannabis products company and Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, reported significant financial and operational progress for the three and twelve months ended December 31, 2024. The company's strong Q4 2024 financial results reflect its strategic expansion into new international markets, cost optimization initiatives, and a diversified product portfolio.

Financial Highlights

* Revenue of $1.1 million in Q4 2024, more than tripling the revenue from the same period last year
* Total revenue of $3.5 million for the twelve-month period, compared to $1.5 million in 2023
* Adjusted EBITDA improved by $1.1 million versus last year, reflecting strong sales growth and reduced costs

Strategic Cost Optimization and Operational Efficiencies

PharmaCielo continues to drive financial discipline, achieving substantial cost reductions while optimizing its operations for long-term growth. The company reduced office and general expenses by $591,000, salaries by $1,189,000, and selling, marketing, and promotion costs by $428,000 compared to 2023. These savings have solidified the company's infrastructure, providing a scalable foundation for future growth and profitability.

Additionally, PharmaCielo has streamlined its operations, right-sized its cultivation capacity, and eliminated non-essential expenditures, creating a leaner and more agile organization. These initiatives have significantly strengthened the company's financial position, aligning resources to maximize growth opportunities and ensuring sustainable success.

Positive Outlook for 2025

With a strong sales pipeline, rising revenues, and ongoing cost reductions, PharmaCielo is on track to achieve positive cash flow and profitability in 2025. The company's first-mover advantage in Colombia, combined with its advanced cultivation and scientific processing capabilities, positions it to capitalize on the expanding global demand for medicinal cannabis.

To support its growing sales pipeline and increased revenues, PharmaCielo will require additional working capital. This need will be met through a private placement, with the majority of the investment coming from insiders and existing shareholders, demonstrating their confidence in the company's long-term growth trajectory.

"As we move into 2025, we are excited about the opportunities ahead," added Mr. Lustig. "Our operational efficiencies, strong product portfolio, and expanding global footprint set the stage for a transformative year. We are committed to delivering sustained value to our shareholders and solidifying PharmaCielo's position as a global leader in the medicinal cannabis industry."

PharmaCielo's strong Q4 2024 financial results, coupled with its strategic cost optimization initiatives and global expansion, position the company well for the growing global demand for medicinal cannabis. As the company continues to execute on its growth strategy, investors can expect to see further progress in its financial performance and market position.